Phenazone: Indication, Dosage, Side Effect, Precaution

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Mild to moderate pain

Adult: 500 mg to 1 g every 4-8 hr. Max: 4 g/day.
Child: 12-15 yr: 500 mg once or bid. Max: 1 g daily. >15 yr: 500 mg to 1 g every 4-8 hr. Max: 4 g/day.

Oral
Acute migraine attacks

Adult: 1 g every 4-8 hr. Max: 4 g/day.
Child: >15 yr: 1 g every 4-8 hr. Max: 4 g/day.

Otic/Aural
Otic inflammation, Removal of earwax

Adult: 4-6 drops (0.5% solution) 3-4 times daily depending on the severity of inflammation.

Contraindications

Allergy to pyrazolones or other NSAIDs. G6PD deficiency, porphyria. Otic/Aural: Perforated eardrums.

Special Precautions

Pregnancy. History of blood disorders.

Adverse Reactions

Hypersensitivity reactions, nephrotoxicity. Nausea, drowsiness, convulsive crisis, agranulocytosis, leucopenia.
Potentially Fatal: Coma (large oral doses), severe skin eruptions.

Drug Interactions

May affect metabolism of drugs metabolised by liver enzymes. Metabolism may be affected by liver enzyme inhibitors or inducers.

Action

Description: Phenazone is an NSAID.
Pharmacokinetics:
Absorption: Absorbed from the GI tract. Peak plasma concentrations within 1-2 hr.
Distribution: Throughout the body fluids; concentrations in the saliva and breast milk reaching about the same levels as those in plasma. Protein-binding: <10%.
Metabolism: Hepatic; metabolised to 3 major metabolites.
Excretion: Mainly via urine; via bile (small amount). Elimination half-life: About 12 hr.

Storage

Otic/Aural:
Store below 25°C.

MIMS Class

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) / Other Ear Preparations

Disclaimer: This information is independently developed by MIMS based on Phenazone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com